Intravacc publishes positive phase I Shigella conjugate vaccine data Bilthoven, The Netherlands, 16 November 2020 –  Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing viral and bacterial vaccines, today announced…

• High medical need for Shigella vaccine
• Over 250 million infections worldwide annually
• Vaccine was well tolerated and induced a significant increase in functional antibodies
• Data published in prestigious journal The Lancet Infectious Diseases

Intravacc appoints Prof. Dr. Virgil Schijns as Chief Scientific Officer Bilthoven, The Netherlands, 5 November 2020 – Intravacc, a global leading contract development and manufacturing organization of viral and bacterial vaccines, today announced the appointment of Prof. Dr. Virgil Schijns,…

Intravacc 2.0 Bilthoven, The Netherlands, 5 October 2020 – After many months of hard work and dedication by our team at Intravacc together with our branding and website agencies, we are pleased to announce the launch of Intravacc 2.0! Our…

• New website and branding
• Matches Intravacc’s aspiration to become a leading vaccine CDMO
• We welcome your feedback on our new website

Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine Bilthoven, The Netherlands, 8 September, 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced that it has been awarded a contract…

• Growing concerns about global spread of this respiratory enterovirus
• Vaccine to protect children from Acute Flaccid Myelitis
• Development of inactivated EV D68 vaccine, through to Phase I clinical testing

Intravacc and Therapyx jointly develop the world’s first prophylactic gonorrhea vaccine Bilthoven, The Netherlands, 25 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, has partnered with American, Buffalo, NY, based Therapyx,…

• Gonorrhea is the second most common bacterial infectious disease worldwide
• Vaccine based on IL12 in combination with intravacc’s gonorrhea OMV targeting mucosal immunization
• Induce an adaptive immune response for long term protection against the gonorrhea bacteria
• Mucosal vaccine platforms offer a broader perspective also for respiratory virus vaccines, such as Covid-19 and influenza

Intravacc’s candidate RSV vaccine demonstrates safety in phase I trial Bilthoven, The Netherlands, 18 August 2020 – Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine,…

• High unmet need for effective pediatric RSV vaccine
• Continued frequent hospitalization of infected infants and risk to elderly
• Partner orientation for further development of this RSV candidate vaccine